Endo (NDOI) Q2 2024 earnings summary

Executive summary

• Emerged from bankruptcy with fresh start accounting, resulting in a new capital structure, clean balance sheet, and modest leverage; all legacy litigation claims were discharged and channeled to trusts.

• Q2 2024 combined revenues were $447 million, down 18% year-over-year, mainly due to declines in Generic Pharmaceuticals and Sterile Injectables, partially offset by growth in Branded and International segments.

• Adjusted EBITDA for Q2 2024 was $176 million, down from $243 million in Q2 2023 but above internal expectations.

• XIAFLEX® remains a key growth driver, supported by new DTC campaigns, robust IP estate extending exclusivity into the 2030s, and a pipeline targeting new indications.

• Leadership transition underway with a new interim CEO appointed and a search for a permanent CEO in progress.

Financial highlights

• Q2 2024 total revenues were $447 million, down 18% year-over-year, with Branded Pharmaceuticals revenue up 6% to $225 million and XIAFLEX® up 8% to $127 million.

• Sterile Injectables revenue declined 34% to $91 million, mainly due to a prior year non-recurring payment and lower Vasostrict sales.

• Generic Pharmaceuticals revenue fell 38% to $110 million, impacted by increased competition, especially for varenicline and dexlansoprazole.

• International Pharmaceuticals revenue increased 10% to $21 million.

• Adjusted net income for Q2 2024 was approximately $105 million, compared to $231 million in Q2 2023.

Outlook and guidance

• 2024 full-year revenue guidance raised to $1.72–$1.78 billion and adjusted EBITDA to $635–$655 million.

• 2025 guidance projects low single-digit revenue growth and mid to high single-digit adjusted EBITDA growth over 2024.

• Branded and sterile injectables segments expected to grow low to mid single digits in 2025; generics flat to mid single-digit decline; international flat.

• Adjusted gross margin for 2024 expected at ~67%; second half margin slightly lower due to product mix.

• Management expects ongoing competitive pressures in generics and sterile injectables to continue impacting revenues.